Skip to main content
. Author manuscript; available in PMC: 2015 Jul 12.
Published in final edited form as: Biol Blood Marrow Transplant. 2014 Oct 16;21(2):300–304. doi: 10.1016/j.bbmt.2014.10.011

Table 2.

Patient Characteristics

Characteristic Case (n = 49) Control (n = 49)
Male 31 (63.3%) 31 (63.3%)
Female 18 (36.7%) 18 (36.7%)
Age, median (range), yr 52.3 (19.1-69.2) 54.3 (20.7-72.5)
Transplantation indication
    ALL 3 (6.1%) 3 (6.1%)
    AML 22 (44.9%) 22 (44.9%)
    Other leukemia 3 (6.1%) 3 (6.1%)
    Myelodysplasia 3 (6.1%) 3 (6.1%)
    Non-Hodgkin lymphoma 14 (28.6%) 14 (28.6%)
    Hodgkin lymphoma 3 (6.1%) 3 (6.1%)
    Myeloproliferative disease 1 (2.0%) 1 (2.0%)
Conditioning
    Myeloablative conditioning 9 (18.4%) 9 (18.4%)
    RIC 40 (81.6%) 40 (81.6%)
Stem cell source
    Bone marrow 2 (4%) 1 (2%)
    PBSC 19 (39%) 16 (33%)
    UCB 28 (57%) 32 (65%)

ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia; PBSC, peripheral blood stem cells; UCB, umbilical cord blood.

Data presented are n (%) unless otherwise indicated.